Frank Rimerman Advisors’s Lam Research LRCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$5.59M Sell
17,004
-815
-5% -$254K 0.31% 47
2026
Q2
$7.72M Buy
17,819
+1,017
+6% +$309K 0.44% 33
2026
Q1
$3.59M Buy
16,802
+13
+0.1% +$2.91K 0.24% 73
2025
Q4
$2.87M Buy
16,789
+86
+0.5% +$13.4K 0.18% 92
2025
Q3
$2.24M Buy
16,703
+1,144
+7% +$121K 0.14% 112
2025
Q2
$1.51M Sell
15,559
-18,181
-54% -$1.44M 0.1% 150
2025
Q1
$2.45M Buy
33,740
+18,681
+124% +$1.47M 0.19% 87
2024
Q4
$1.09M Sell
15,059
-1,081
-7% -$82K 0.08% 187
2024
Q3
$1.32M Sell
16,140
-12,980
-45% -$1.13M 0.09% 174
2024
Q2
$3.1M Buy
29,120
+29,040
+36,300% +$2.79M 0.22% 73
2024
Q1
$7.77K Hold
80
– – ﹤0.01% 186
2023
Q4
$6.27K Buy
+80
New +$5.45K ﹤0.01% 189
2022
Q2
– Sell
-13,110
Closed -$705K – 108
2022
Q1
$705K Hold
13,110
– – 0.23% 60
2021
Q4
$943K Buy
13,110
+5,140
+64% +$322K 0.32% 47
2021
Q3
$454K Buy
+7,970
New +$485K 0.18% 68

Other funds holding LRCX

Frank Rimerman Advisors's LRCX Position: Q3 2026 in Review

Frank Rimerman Advisors reduced its Lam Research (LRCX) stake by 4.6% in Q3 2026, selling an estimated $254K and leaving 17,004 shares worth $5.59M. The position accounts for 0.31% of the portfolio, ranked #47.

Frank Rimerman Advisors first reported a position in LRCX in Q3 2021 and has held it in 15 quarters since. The position peaked at $7.72M in Q2 2026. 2,973 funds tracked by Wall St. Rank hold LRCX as of Q3 2026.

  • Frank Rimerman Advisors held 17,004 shares of Lam Research worth $5.59M as of Q3 2026.
  • Frank Rimerman Advisors sold 815 Lam Research shares in Q3 2026, an estimated $254K.
  • Lam Research made up 0.31% of Frank Rimerman Advisors's portfolio in Q3 2026, its #47 holding.
  • Frank Rimerman Advisors first reported a position in Lam Research in Q3 2021 and has held it in 15 quarters since.
  • Frank Rimerman Advisors's Lam Research position peaked at $7.72M in Q2 2026.
  • 2,973 funds tracked by Wall St. Rank held Lam Research as of Q3 2026.

Based on Frank Rimerman Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.